Li-Na Liu1,2, Yan-Mei Mao1,2, Chan-Na Zhao1,2, Hong Wang1,2, Fei-Fei Yuan1,2, Xiao-Mei Li3, Hai-Feng Pan1,2. 1. a Department of Epidemiology and Biostatistics , School of Public Health, Anhui Medical University , Hefei , Anhui , China. 2. b Department of causes and interventions of chronic diseases , Anhui Province Key Laboratory of Major Autoimmune Diseases , Hefei , Anhui , China. 3. c Department of Rheumatology , Anhui Provincial Hospital , Hefei , Anhui , China.
Abstract
OBJECTIVE: Currently published data regarding the potential role of osteoprotegerin (OPG), osteocalcin (OCN) and osteopontin (OPN) for the discrimination between rheumatoid arthritis (RA) and osteoarthritis (OA) are contradictory. To derive a more precise evaluation, a meta-analysis was performed. METHODS: Published literatures comparing plasma/serum OPG, OCN and OPN levels between RA group and OA controls were searched in PubMed, Embase and the Cochrane Library. The Newcastle-Ottawa Scale was used to assess the study quality. Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated by random-effect model analysis. Heterogeneity test was performed by the Q statistic and quantified using I2. RESULTS: Nine studies including 438 RA patients and 255 OA patients were finally incorporated in the meta-analysis after examining title, type, abstracts and full text. The results showed that RA patients had higher plasma/serum OPN (pooled SMD = -2.57, 95% CI = -4.72 to -0.41) levels when compared to OA patients. No significant difference in plasma/serum OPG (pooled SMD = -0.29, 95% CI = -1.07‒0.49) and OCN (pooled SMD = -0.09, 95% CI = -0.48‒0.31) levels were found between RA patients and OA patients. Subgroup analysis indicated that plasma/serum OPG levels had no significant differences between RA patients and OA patients in Europe and Asian. CONCLUSIONS: Overall, there is no significant difference in circulating OPG and OCN levels between RA patients and OA patients. However, plasma/serum OPN level is significantly higher in RA patients compared with OA patients.
OBJECTIVE: Currently published data regarding the potential role of osteoprotegerin (OPG), osteocalcin (OCN) and osteopontin (OPN) for the discrimination between rheumatoid arthritis (RA) and osteoarthritis (OA) are contradictory. To derive a more precise evaluation, a meta-analysis was performed. METHODS: Published literatures comparing plasma/serum OPG, OCN and OPN levels between RA group and OA controls were searched in PubMed, Embase and the Cochrane Library. The Newcastle-Ottawa Scale was used to assess the study quality. Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated by random-effect model analysis. Heterogeneity test was performed by the Q statistic and quantified using I2. RESULTS: Nine studies including 438 RApatients and 255 OA patients were finally incorporated in the meta-analysis after examining title, type, abstracts and full text. The results showed that RApatients had higher plasma/serum OPN (pooled SMD = -2.57, 95% CI = -4.72 to -0.41) levels when compared to OA patients. No significant difference in plasma/serum OPG (pooled SMD = -0.29, 95% CI = -1.07‒0.49) and OCN (pooled SMD = -0.09, 95% CI = -0.48‒0.31) levels were found between RApatients and OA patients. Subgroup analysis indicated that plasma/serum OPG levels had no significant differences between RApatients and OA patients in Europe and Asian. CONCLUSIONS: Overall, there is no significant difference in circulating OPG and OCN levels between RApatients and OA patients. However, plasma/serum OPN level is significantly higher in RApatients compared with OA patients.
Authors: Rgda Mohamed Osman; Mounkaila Noma; Abdallah Elssir Ahmed; Hanadi Abdelbagi; Rihab Ali Omer; Musab M Ali; Ayman Ali Mohammed Alameen; Ali Mahmoud Edris; Mohamed S Muneer; Omayma Siddig; Rowa Hassan; Eiman Siddig Ahmed; Lamis Ahmed Hassan; Osama El Hadi Bakheet; Ayman Ahmed; Nouh Saad Mohamed; Emmanuel Edwar Siddig Journal: SAGE Open Med Date: 2021-05-31